scholarly journals Inhibitory Effects of Dopamine Receptor D1 Agonist on Mammary Tumor and Bone Metastasis

2017 ◽  
Vol 7 (1) ◽  
Author(s):  
Kazumasa Minami ◽  
Shengzhi Liu ◽  
Yang Liu ◽  
Andy Chen ◽  
Qiaoqiao Wan ◽  
...  
Keyword(s):  
Bone Metastasis ◽  
Dopamine Receptor ◽  
Mammary Tumor ◽  
Inhibitory Effects ◽  
D1 Agonist

scholarly journals Human non-functioning pituitary tumors invasiveness: inhibitory effects of dopamine receptor type 2 (DRD2) agonist and cofilin involvement

2016 ◽  
Author(s):  
Erika Peverelli ◽  
Elena Giardino ◽  
Donatella Treppiedi ◽  
Marco Locatelli ◽  
Valentina Vaira ◽  
...  
Keyword(s):  
Dopamine Receptor ◽  
Pituitary Tumors ◽  
Receptor Type ◽  
Inhibitory Effects

scholarly journals Characterization of PF-6142, a Novel, Non-Catecholamine Dopamine Receptor D1 Agonist, in Murine and Nonhuman Primate Models of Dopaminergic Activation

2020 ◽  
Author(s):  
Kozak R ◽  
Kiss T ◽  
Dlugolensi K ◽  
Johnson D ◽  
Gorczyca RR ◽  
...  
Keyword(s):  
Dopamine Receptor ◽  
Nonhuman Primate ◽  
D1 Agonist ◽  
Dopaminergic Activation

scholarly journals CXCR2: A Novel Mediator of Mammary Tumor Bone Metastasis

2019 ◽  
Vol 20 (5) ◽  
pp. 1237 ◽  
Author(s):  
Bhawna Sharma ◽  
Kalyan Nannuru ◽  
Sugandha Saxena ◽  
Michelle Varney ◽  
Rakesh Singh
Keyword(s):  
Breast Cancer ◽  
Bone Metastasis ◽  
Tumor Cell ◽  
Cancer Patients ◽  
Mammary Tumor ◽  
Critical Role ◽  
Breast Cancer Patients ◽  
Mammary Tumor Cell ◽  
Primary Tumors

Most breast cancer patients die due to bone metastasis. Although metastasis accounts for 5% of the breast cancer cases, it is responsible for most of the deaths. Sometimes even before the detection of a primary tumor, most of the patients have bone and lymph node metastasis. Moreover, at the time of death, breast cancer patients have the bulk of the tumor burden in their bones. Therapy options are available for the treatment of primary tumors, but there are minimal options for treating breast cancer patients who have bone metastasis. C-X-C motif chemokine receptor type 2 (CXCR2) receptor-mediated signaling has been shown to play a critical role during bone-related inflammations and its ligands C-X-C motif chemokine ligand 6 (CXCL6) and 8 (CXCL8) aid in the resorption of bone during bone metastasis. In this study, we tested the hypothesis that CXCR2 contributes to mammary tumor-induced osteolysis and bone metastasis. In the present study, we examined the role of both tumor cell-derived and host-derived CXCR2 in influencing mammary tumor cell bone metastasis. For understanding the role of tumor cell-derived CXCR2, we utilized Cl66 CXCR2 knockdown (Cl66-shCXCR2) and Cl66-Control cells (Cl66-Control) and observed a significant decrease in tumor growth and tumor-induced osteolysis in Cl66-shCXCR2 cells in comparison with the Cl66-Control cells. Next, for understanding the role of host-derived CXCR2, we utilized mice with genomic knockdown of CXCR2 (Cxcr2−/−) and injected Cl66-Luciferase (Cl66-Luc) or 4T1-Luciferase (4T1-Luc) cells. We observed decreased bone destruction and metastasis in the bone of Cxcr2−/− mice. Our data suggest the importance of both tumor cell- and host-derived CXCR2 signaling in the bone metastasis of breast cancer cells.

Activation of Phosphatidylinositol-Linked Novel D1 Dopamine Receptors Inhibits High-Voltage-Activated Ca2+ Currents in Primary Cultured Striatal Neurons

2009 ◽  
Vol 101 (5) ◽  
pp. 2230-2238 ◽  
Author(s):  
Li-Qun Ma ◽  
Chao Liu ◽  
Fang Wang ◽  
Na Xie ◽  
Jun Gu ◽  
...  
Keyword(s):  
Dopamine Receptor ◽  
High Voltage ◽  
Dependent Manner ◽  
Striatal Neurons ◽  
Inhibitory Effects ◽  
Patch Clamp Technique ◽  
Whole Cell Patch Clamp ◽  
Intracellular Ca ◽  
Dose Dependent

Recent evidences indicate the existence of a putative novel phosphatidylinositol (PI)-linked D1 dopamine receptor that mediates excellent anti-Parkinsonian but less severe dyskinesia action. To further understand the basic physiological function of this receptor in brain, the effects of a PI-linked D1 dopamine receptor-selective agonist 6-chloro-7,8-dihydroxy-3-methyl-1-(3-methylphenyl)-2,3,4,5-tetrahydro-1H-3-benzazepine (SKF83959) on high-voltage activated (HVA) Ca2+ currents in primary cultured striatal neurons were investigated by whole cell patch-clamp technique. The results indicated that stimulation by SKF83959 induced an inhibition of HVA Ca2+ currents in a dose-dependent manner in substance-P (SP)-immunoreactive striatal neurons. Application of D1 receptor, but not D2, α1 adrenergic, 5-HT receptor, or cholinoceptor antagonist prevented SKF83959-induced reduction, indicating that a D1 receptor-mediated event assumed via PI-linked D1 receptor. SKF83959-induced inhibitory modulation was mediated by activation of phospholipase C (PLC), mobilization of intracellular Ca2+ stores and activation of calcineurin. Furthermore, the inhibitory effects were attenuated significantly by the L-type calcium channel antagonist nifedipine, suggesting that L-type calcium channels involved in the regulation induced by SKF83959. These findings may help to further understand the functional role of the PI-linked dopamine receptor in brain.

P23. Inhibitory effects of baicalein, baicalin and wogonin on osteolytic bone metastasis of breast cancer

2008 ◽  
Vol 34 ◽  
pp. 21-22 ◽  
Author(s):  
Ji-Hee Won ◽  
Kwang-Kyun Park ◽  
Won-Yoon Chung
Keyword(s):  
Breast Cancer ◽  
Bone Metastasis ◽  
Inhibitory Effects ◽  
Osteolytic Bone Metastasis

Inhibitory effects of partial D2 dopamine receptor agonists on the d-amphetamine discriminative cue

1989 ◽  
Vol 1 (2) ◽  
pp. 101???112 ◽  
Author(s):  
M. Exner ◽  
L. J. Furmidge ◽  
F. J. White ◽  
D. Clark
Keyword(s):  
Dopamine Receptor ◽  
Inhibitory Effects ◽  
D2 Dopamine Receptor ◽  
Dopamine Receptor Agonists ◽  
Receptor Agonists ◽  
Discriminative Cue

The antipsychotic potential of l-stepholidine—a naturally occurring dopamine receptor D1 agonist and D2 antagonist

2008 ◽  
Vol 199 (2) ◽  
pp. 275-289 ◽  
Author(s):  
Sridhar Natesan ◽  
Greg E. Reckless ◽  
Karen B. L. Barlow ◽  
John Odontiadis ◽  
José N. Nobrega ◽  
...  
Keyword(s):  
Dopamine Receptor ◽  
Naturally Occurring ◽  
D1 Agonist ◽  
D2 Antagonist

scholarly journals Inhibitory effects of the selective dopamine receptor agonists, B-HT 920 and SND 919, on prolactin release from rat anterior pituitary gland in vivo and in vitro

1989 ◽  
Vol 49 ◽  
pp. 225
Author(s):  
Mariko Domae ◽  
Shin-ichiro Matsumoto ◽  
Katsushi Yamada ◽  
Yasuhiko Hanabusa ◽  
Tatsuo Furukawa
Keyword(s):  
Pituitary Gland ◽  
Dopamine Receptor ◽  
Anterior Pituitary ◽  
Inhibitory Effects ◽  
Prolactin Release ◽  
Dopamine Receptor Agonists ◽  
Snd 919 ◽  
Selective Dopamine

scholarly journals Characterization of PF-6142, a Novel, Non-Catecholamine Dopamine Receptor D1 Agonist, in Murine and Nonhuman Primate Models of Dopaminergic Activation

2020 ◽  
Vol 11 ◽  
Author(s):  
Rouba Kozak ◽  
Tamás Kiss ◽  
Keith Dlugolenski ◽  
David E. Johnson ◽  
Roxanne R. Gorczyca ◽  
...  
Keyword(s):  
Dopamine Receptor ◽  
Nonhuman Primate ◽  
D1 Agonist ◽  
Dopaminergic Activation
Sign in / Sign up

Export Citation Format

Share Document